Who is sponsoring NCT00074230?

NCT00074230 is sponsored by University Hospital Erlangen.

What condition does NCT00074230 study?

NCT00074230 studies Melanoma (Skin).

What drugs are being tested in NCT00074230?

Interventions: Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin.

What is the status of NCT00074230?

NCT00074230 is currently COMPLETED.

Last reviewed 2015-05-11 · How we verify

Vaccination of Stage IV Cutaneous Melanoma Patients With Mature, Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding for Mage-3, MelanA, and Survivin Antigens

NCT00074230 Phase 1/Phase 2 COMPLETED

RATIONALE: Vaccines made from a person's dendritic cells and antigens may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy using autologous dendritic cells with antigens in treating patients who have stage IV cutaneous melanoma.

Details

Lead sponsor	University Hospital Erlangen
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	82
Start date	2003-07
Completion	2014-03

Conditions

Melanoma (Skin)

Interventions

Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin

Primary outcomes

Safety and tolerability at every visit — 3 months
Overall survival as assessed by clinical staging (CT scan, positron emission tomography [PET]) every 3 months — 3 months

Countries

Germany